<DOC>
	<DOCNO>NCT02016833</DOCNO>
	<brief_summary>This study clinical study aim establish immunological assay qualitative quantitative evaluation WT-1 , Survivin HPV16 E7-specific immune response cancer patient . Such study allow development suitable immunological tool use assess response subsequent phase I study aim evaluate therapeutic vaccine candidate target WT-1 , Survivin and/or HPV16 E7-expressing tumor . In addition , study help define baseline cancer-associated immune response select patient population . Cervical ovarian cancer patient , well leukemia patient , include study . WT-1 , Survivin HPV-specific immune response monitor patient ex vivo culture IFNg ELISpot well tetramer stain .</brief_summary>
	<brief_title>Development Immunological Assays Evaluation Tumor Antigen Specific Immunity</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Cystadenocarcinoma , Serous</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Specific Inclusion criterion For ovarian cancer patient : Histologically confirm surgical diagnosis highgrade serous ( undifferentiated ) ovarian cancer For CIN3 cervical cancer patient : Histologically confirm diagnosis CIN3 cervical cancer For AML CML patient : HLAA2 positivity diagnosis AML CML confirm bone marrow biopsy peripheral blood Shared inclusion criterion No evidence active progressive disease . For ovarian cancer patient , woman rise CA125 negative imaging acceptable Age â‰¥ 18 yr &lt; 70 yr ECOG 02 Adequate hematologic assessment ( result previous standard care visit ) : Absolute neutrophil count ( ANC ) great equal 1.0 x 109/L Platelets great equal 100 x 109/L . Written informed consent Treatment chemotherapy , radiation therapy , immunotherapy nontopical steroid within past 3 week prior initiation study . Immunosuppressive therapy ( exclude topical steroid ) condition . Recurrent/progressive disease confirm clinically , radiologically histologically entry study . ( exclude versus inclusion criterion ) Persistent fever ( &gt; 24 hour ) document repeated measurement active uncontrolled infection last 4 week . Active autoimmune disease , include , limited , SLE , MS , ankylose spondylitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Cervical Cancer</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Immunity</keyword>
	<keyword>WT-1</keyword>
	<keyword>Survivin</keyword>
	<keyword>HPV</keyword>
</DOC>